Find a Clinical Trial | Pfizer Clinical Trials

Pneumococcal vaccine study for toddlers 12 to 15 months old

We’re working closely with pediatricians and researchers to expand protection for toddlers against pneumococcal disease.

Learn more

22 trials found for breast cancer

Recruiting

A Study of SGN-B6A in Advanced Solid Tumors

Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous

A Study of SGN-B7H4V in Advanced Solid Tumors

Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung,

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Breast Cancer, Head and Neck Cancer

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Breast Neoplasms

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

HER2-positive Breast Cancer

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Ovarian Neoplasms, Melanoma, Triple Negative Breast Neoplasms, Gastric Cancer

Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

Breast Neoplasm

Swedish Ibrance Registries Insights (SIRI)

Malignant Neoplasm of Breast

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

Metastatic Breast Cancer

Male or Female

18 - 90 years

12study location(s)